Wall Street analysts will be watching closely when Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reports its quarterly earnings next, which is scheduled for Thu 21 Feb (In 39 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at $0.01 per share. In the preceding quarter, the company reportedly generated EPS of -$0.38 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of -71.60%, a profit margin of -82.10% and a gross margin of 93.50%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Most recently, on November 7th, 2018, JP Morgan Downgrade a Underweight rating. Before that, on November 7th, 2018, Credit Suisse Downgrade to Neutral. H.C. Wainwright Initiated a Sell rating on July 23rd, 2018, Morgan Stanley Downgrade an Underweight rating on May 9th, 2018, and BofA/Merrill Downgrade a Underperform rating on January 5th, 2018.
At its current price point, combined with the fact that this company has 152.48M shares outstanding, the current market capitalization sits at 1.93B. In the last trading day, 812,395 shares of Ironwood Pharmaceuticals, Inc. were traded, which compares to its usual volume of about 1.57M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $1.69 in the past five trading days, resulting in a percentage change of +15.36% and a moving average of 12.21. In the past 20 days, its price changed by $1.15 (which is +9.97%) and the stock’s moving average was 10.83. Looking back a full 50 days, shares of IRWD changed by -$3.40 (which is -21.13%) and demonstrated a moving average of 11.91.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 86.64%, a 14-day Stochastic %K score of 87.87% and a 20-day Stochastic %K score of 87.87%. Using a similar metric, Ironwood Pharmaceuticals, Inc. (IRWD) shares showed a Stochastic %D of 89.91% over the past 9 days, a Stochastic %D score of 89.05% over the last 14 days, and a 20-day Stochastic %D of 83.62%. Meanwhile, this stock’s MACD Oscillator was 1.11 over the past 9 days, 1.74 over the past two weeks, and 1.70 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $12.69 level. Over the past 12 months, this stock has experienced a high price of $21.20 and a low of $9.07. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
Wellington Management Co LLP purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 19,433,137 shares of the company’s stock following the addition of 169,870 to this investor’s holdings during the three-month period. This share count represents that Wellington Management Co LLP now held 13.87% stake in Ironwood Pharmaceuticals, Inc. (IRWD)’s shares.
Just in the most recent trading day, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) experienced a high price of $12.86 and low point of $12.285. At the end of the last trading session, this stock was at 12.69 per share, following a loss of -$0.07, or 1.04% during the full day.